



PATENT
New Attorney Docket No. **03495.0380-00000**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Pierre DRUILHE et al.)	Group Art Unit: 1645
)	
Application No.: 10/712,533)	Examiner: Nita M. Minnifield
)	
Filed: November 14, 2003)	
)	
For: PLASMODIUM FALCIPARUM)	Confirmation No.: 5870
ANTIGENS AND THEIR)	
VACCINE AND DIAGNOSTIC)	
APPLICATIONS)	

Mail Stop Sequence
Commissioner for Patents
P.O. Box 22313-1450
Alexandria, VA 22313-1450

Sir:

SUBMISSION OF SUBSTITUTE SEQUENCE LISTING

Applicants enclose a substitute paper copy of the Sequence Listing hereby submitted to comply with the Notice to Comply with Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures mailed on May 21, 2008. In particular, the listing is amended to include the inventor's names at <110>, the application serial number at <140>, and the current filing date at <141>.


In connection with the Substitute Sequence Listing submitted concurrently herewith, the undersigned hereby states that on information and belief the submission does not include new matter and the content of the paper copy of the Substitute

Sequence Listing and of the computer readable copy of the Substitute Sequence Listing are the same.

Should any fees be required to comply with this requirement, please charge our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: 

Kenneth J. Meyers
Reg. No. 25,146
Tel.: 202 408-4033
Fax.: 202 408-4400
ken.meyers@finnegan.com

Dated: June 4, 2008



Notice to Comply

Application No.

10/712533

Applicant(s)

Pierre Druilhe

Examiner

N. M. Minnifield

Art Unit

1645

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. According to MPEP 2424, the sequence listing should include <110>, Preferably max. of 10 names; one name per line; preferable format: Surname, Other Names and/or Initials as well as other mandatory requirements are necessary. The RSL filed November 16, 2004 lists the company name not the inventors. <140> should list the current application number 10/712533. Correction is required.

Applicant Must Provide:

- ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-0731 or (571) 272-0951

For CRF Submission Help, call (571) 272-2510

PatentIn Software Program Support

Technical Assistance. 1-866-217-9197 or 703-305-3028 or 571-272-6845

PatentIn Software is Available At www.USPTO.gov

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

/N. M. Minnifield/
Primary Examiner,
Art Unit 1645